IL321857A - פורמולציות rna לשימוש פרמצבטי - Google Patents

פורמולציות rna לשימוש פרמצבטי

Info

Publication number
IL321857A
IL321857A IL321857A IL32185725A IL321857A IL 321857 A IL321857 A IL 321857A IL 321857 A IL321857 A IL 321857A IL 32185725 A IL32185725 A IL 32185725A IL 321857 A IL321857 A IL 321857A
Authority
IL
Israel
Prior art keywords
pharmaceutical use
rna formulations
rna
formulations
pharmaceutical
Prior art date
Application number
IL321857A
Other languages
English (en)
Inventor
Ugur Sahin
Katalin Karik?
Sergey Bessonov
Thomas Ziegenhals
Stephanie Fesser
Anna Ernst
G?bor BOROS
Jonas Reinholz
Irena Vlatkovic
Azita Mahiny
Original Assignee
BioNTech SE
Ugur Sahin
Katalin Karik?
Sergey Bessonov
Thomas Ziegenhals
Stephanie Fesser
Anna Ernst
G?bor BOROS
Jonas Reinholz
Irena Vlatkovic
Azita Mahiny
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BioNTech SE, Ugur Sahin, Katalin Karik?, Sergey Bessonov, Thomas Ziegenhals, Stephanie Fesser, Anna Ernst, G?bor BOROS, Jonas Reinholz, Irena Vlatkovic, Azita Mahiny filed Critical BioNTech SE
Publication of IL321857A publication Critical patent/IL321857A/he

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7105Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/5123Organic compounds, e.g. fats, sugars
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67General methods for enhancing the expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141MicroRNAs, miRNAs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL321857A 2023-01-18 2025-06-30 פורמולציות rna לשימוש פרמצבטי IL321857A (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2023/051117 WO2024153324A1 (en) 2023-01-18 2023-01-18 Rna formulations for pharmaceutical use
PCT/EP2024/050983 WO2024153675A1 (en) 2023-01-18 2024-01-17 Rna formulations for pharmaceutical use

Publications (1)

Publication Number Publication Date
IL321857A true IL321857A (he) 2025-08-01

Family

ID=85037171

Family Applications (1)

Application Number Title Priority Date Filing Date
IL321857A IL321857A (he) 2023-01-18 2025-06-30 פורמולציות rna לשימוש פרמצבטי

Country Status (6)

Country Link
EP (1) EP4652270A1 (he)
JP (1) JP2026508822A (he)
CN (1) CN120712350A (he)
AU (1) AU2024210882A1 (he)
IL (1) IL321857A (he)
WO (2) WO2024153324A1 (he)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026061971A1 (en) 2024-09-17 2026-03-26 Lonza Ltd Nucleic acid untranslated regions

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
ES2655912T3 (es) 2002-11-08 2018-02-22 Ablynx N.V. Anticuerpos de dominio simple dirigidos contra factor de necrosis tumoral-alfa y usos para los mismos
ES2567634T3 (es) 2004-02-09 2016-04-25 Human Genome Sciences, Inc. Proteínas de fusión de albúmina
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
US20070269422A1 (en) 2006-05-17 2007-11-22 Ablynx N.V. Serum albumin binding proteins with long half-lives
WO2008012629A2 (en) 2006-07-24 2008-01-31 Biorexis Pharmaceutical Corporation Exendin fusion proteins
CN101646689A (zh) 2006-09-08 2010-02-10 埃博灵克斯股份有限公司 具有长半衰期的血清清蛋白结合蛋白
JP2011507543A (ja) 2007-12-27 2011-03-10 ノバルティス アーゲー 改善されたフィブロネクチンベースの結合分子およびそれらの使用
PL2274331T3 (pl) 2008-05-02 2014-04-30 Novartis Ag Ulepszone cząsteczki wiążące oparte na fibronektynie i ich zastosowanie
CN102812014B (zh) 2009-10-30 2016-01-20 多美恩医疗公司 新颖的肟衍生物及其作为代谢型谷氨酸受体的别构调节剂的用途
US10233228B2 (en) 2010-04-09 2019-03-19 Albumedix Ltd Albumin derivatives and variants
EA022983B1 (ru) 2010-04-13 2016-04-29 Бристол-Майерс Сквибб Компани Белки на основе структурного домена фибронектина, связывающие pcsk9
US20140220017A1 (en) 2011-09-23 2014-08-07 Universitat Stuttgart Serum half-life extension using igbd
EP2780364A2 (en) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
WO2016005004A1 (en) 2014-07-11 2016-01-14 Biontech Rna Pharmaceuticals Gmbh Stabilization of poly(a) sequence encoding dna sequences
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
IL307179A (he) 2015-10-28 2023-11-01 Acuitas Therapeutics Inc ליפידים חדשים ופורמולציות ננוחלקיקים של ליפידים למתן חומצות גרעין
BR112018069417A2 (pt) 2016-04-22 2019-01-22 Biontech Rna Pharmaceuticals Gmbh método para fornecer rna fita simples e ssrna
ES3063077T3 (en) 2016-10-26 2026-04-15 Acuitas Therapeutics Inc Lipid nanoparticle formulations
JP7423521B2 (ja) * 2017-11-22 2024-01-29 モダーナティエックス・インコーポレイテッド フェニルケトン尿症の治療用のフェニルアラニンヒドロキシラーゼをコードするポリヌクレオチド
WO2020047201A1 (en) * 2018-09-02 2020-03-05 Modernatx, Inc. Polynucleotides encoding very long-chain acyl-coa dehydrogenase for the treatment of very long-chain acyl-coa dehydrogenase deficiency
EP4126069A1 (en) 2020-03-25 2023-02-08 BioNTech SE Rna particles comprising polysarcosine
EP3901261A1 (en) 2020-04-22 2021-10-27 BioNTech RNA Pharmaceuticals GmbH Coronavirus vaccine
CA3171589A1 (en) * 2021-05-03 2022-11-03 Moritz THRAN Improved nucleic acid sequence for cell type specific expression

Also Published As

Publication number Publication date
WO2024153324A1 (en) 2024-07-25
WO2024153675A1 (en) 2024-07-25
JP2026508822A (ja) 2026-03-13
EP4652270A1 (en) 2025-11-26
AU2024210882A1 (en) 2025-07-17
CN120712350A (zh) 2025-09-26

Similar Documents

Publication Publication Date Title
SG11202109102PA (en) Pharmaceutical formulations
EP4188329A4 (en) PHARMACEUTICAL FORMULATIONS CONTAINING TADALAFIL
IL321857A (he) פורמולציות rna לשימוש פרמצבטי
GB202010230D0 (en) Pharmaceutical formulation
GB202005282D0 (en) Pharmaceutical Formulations
GB202100526D0 (en) Pharmaceutical formulation
ZA202212663B (en) Pharmaceutical formulations
EP4034120A4 (en) SOLID ORAL PHARMACEUTICAL FORMULATIONS COMPRISING SAPROPTERIN DICHLORHYDRATE AND AT LEAST ONE PHARMACEUTICAL EXCIPIENT
IL307803A (he) פורמולציות הידרונידון רוקחיות למחלות
IL314206A (he) פורמולציה תרופתית
HK40128321A (en) Rna formulations for pharmaceutical use
CA3279723A1 (en) Rna formulations for pharmaceutical use
GB202003108D0 (en) Pharmaceutical formulations
GB202001439D0 (en) Drug formulations
IL314046A (he) תכשירים תרופתיים של ribociclib
IL297081A (he) פורמולציה רוקחית
GB202307626D0 (en) Pharmaceutical formulations
IL308250A (he) פורמולציות תרופתיות
GB202112820D0 (en) Pharmaceutical formulations
GB202417264D0 (en) Pharmaceutical formulations
GB202417258D0 (en) Pharmaceutical formulations
GB202417250D0 (en) Pharmaceutical formulations
GB202015273D0 (en) Solid form pharmaceutical formulations
IL321640A (he) תכשיר רפואי
IL319214A (he) פורמולציה רוקחית